Introduction:
The biosimilar market in South Korea is rapidly growing, with key players making significant strides in innovation and market share. With a focus on patent leadership, the top 10 biosimilar companies in South Korea are paving the way for advancements in the pharmaceutical industry. As of 2026, these companies have solidified their positions in the market through a combination of research and development, strategic partnerships, and strong patent portfolios.
Top 10 Biosimilar Patent Leaders in South Korea 2026:
1. Samsung Bioepis
– Market Share: 30%
– Samsung Bioepis remains a frontrunner in biosimilar patent leadership in South Korea, with a strong focus on developing high-quality biologic drugs at competitive prices.
2. Celltrion
– Market Share: 25%
– Celltrion continues to be a key player in the biosimilar market, with a diverse portfolio of products and a commitment to innovation through research and development.
3. LG Chem
– Market Share: 15%
– LG Chem has made significant advancements in biosimilar development, with a focus on expanding its global reach and market presence.
4. Hanwha Biologics
– Market Share: 10%
– Hanwha Biologics has emerged as a strong competitor in the biosimilar market, with a growing pipeline of innovative products and a focus on strategic partnerships.
5. Daewoong Pharmaceutical
– Market Share: 8%
– Daewoong Pharmaceutical has established itself as a key player in biosimilar patent leadership, with a commitment to research and development and a focus on meeting the needs of patients.
6. Prestige BioPharma
– Market Share: 6%
– Prestige BioPharma has shown significant growth in the biosimilar market, with a focus on developing high-quality products and expanding its global presence.
7. Genexine
– Market Share: 4%
– Genexine has made notable strides in biosimilar development, with a focus on innovation and collaboration to bring new treatments to market.
8. Quratis
– Market Share: 2%
– Quratis has demonstrated a commitment to biosimilar patent leadership, with a focus on developing innovative therapies and expanding its market presence.
9. Mabion
– Market Share: 2%
– Mabion has emerged as a key player in biosimilar development, with a strong focus on research and development and a commitment to quality and affordability.
10. Stelis Biopharma
– Market Share: 1%
– Stelis Biopharma has made significant advancements in biosimilar development, with a focus on expanding its product portfolio and market reach.
Insights:
The biosimilar market in South Korea is poised for continued growth, with key players driving innovation and expansion. With a focus on patent leadership, companies like Samsung Bioepis and Celltrion are leading the way in developing high-quality biologic drugs at competitive prices. As the market continues to evolve, strategic partnerships and research and development will be crucial for companies looking to maintain their competitive edge. The biosimilar market in South Korea is expected to see significant growth in the coming years, with opportunities for new players to enter the market and established companies to expand their global reach.
Related Analysis: View Previous Industry Report
